Does the media prefer LIVN or BAX?

In the previous week, Baxter International had 25 more articles in the media than LivaNova. MarketBeat recorded 30 mentions for Baxter International and 5 mentions for LivaNova. Baxter International's average media sentiment score of 1.00 beat LivaNova's score of 0.14 indicating that Baxter International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Baxter International 15 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, PEN or LIVN?

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.50B 8.49 $177.69M $4.07 79.67 LivaNova $1.39B 3.15 -$242.47M $3.38 23.51

Is PEN or LIVN more profitable?

LivaNova has a net margin of 12.82% compared to Penumbra's net margin of 10.67%. LivaNova's return on equity of 16.35% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 10.67% 10.50% 8.17% LivaNova 12.82% 16.35% 7.76%

Does the media refer more to PEN or LIVN?

In the previous week, Penumbra had 2 more articles in the media than LivaNova. MarketBeat recorded 7 mentions for Penumbra and 5 mentions for LivaNova. Penumbra's average media sentiment score of 1.54 beat LivaNova's score of 0.14 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive LivaNova 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, SNN or LIVN?

Smith & Nephew SNATS has higher revenue and earnings than LivaNova. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 1.99 $625M N/A N/A LivaNova $1.39B 3.15 -$242.47M $3.38 23.51

Does the media favor SNN or LIVN?

In the previous week, Smith & Nephew SNATS had 6 more articles in the media than LivaNova. MarketBeat recorded 11 mentions for Smith & Nephew SNATS and 5 mentions for LivaNova. Smith & Nephew SNATS's average media sentiment score of 0.82 beat LivaNova's score of 0.14 indicating that Smith & Nephew SNATS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, GMED or LIVN?

Globus Medical has higher revenue and earnings than LivaNova. Globus Medical is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $2.94B 3.80 $537.87M $3.91 21.25 LivaNova $1.39B 3.15 -$242.47M $3.38 23.51

Is GMED or LIVN more profitable?

Globus Medical has a net margin of 17.02% compared to LivaNova's net margin of 12.82%. LivaNova's return on equity of 16.35% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets Globus Medical 17.02% 14.57% 12.62% LivaNova 12.82% 16.35% 7.76%

Does the media refer more to GMED or LIVN?

In the previous week, Globus Medical had 2 more articles in the media than LivaNova. MarketBeat recorded 7 mentions for Globus Medical and 5 mentions for LivaNova. Globus Medical's average media sentiment score of 0.71 beat LivaNova's score of 0.14 indicating that Globus Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, LIVN or GKOS?

Glaukos has lower revenue, but higher earnings than LivaNova. Glaukos is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.15 -$242.47M $3.38 23.51 Glaukos $612.84M 17.39 -$187.69M -$3.25 N/A

Is LIVN or GKOS more profitable?

LivaNova has a net margin of 12.82% compared to Glaukos' net margin of -30.68%. LivaNova's return on equity of 16.35% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 12.82% 16.35% 7.76% Glaukos -30.68% -6.37% -4.78%

Does the media prefer LIVN or GKOS?

In the previous week, Glaukos had 21 more articles in the media than LivaNova. MarketBeat recorded 26 mentions for Glaukos and 5 mentions for LivaNova. Glaukos' average media sentiment score of 0.89 beat LivaNova's score of 0.14 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 7 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

LivaNova (LIVN) Competitors

$79.46 +1.20 (+1.53%)

As of 03:53 PM Eastern

Compare

LIVN vs. BAX, PEN, SNN, GMED, and GKOS

Should you buy LivaNova stock or one of its competitors? LivaNova's main competitors and comparable companies include Baxter International (BAX), Penumbra (PEN), Smith & Nephew SNATS (SNN), Globus Medical (GMED), and Glaukos (GKOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does LivaNova compare to Baxter International?

LivaNova (NASDAQ:LIVN) and Baxter International (NYSE:BAX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 90.2% of Baxter International shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 0.2% of Baxter International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

LivaNova has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Baxter International has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

LivaNova presently has a consensus price target of $83.50, suggesting a potential upside of 5.09%. Baxter International has a consensus price target of $22.45, suggesting a potential downside of 14.49%. Given LivaNova's stronger consensus rating and higher possible upside, equities research analysts plainly believe LivaNova is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
Baxter International	2 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

LivaNova has a net margin of 12.82% compared to Baxter International's net margin of -9.27%. Baxter International's return on equity of 16.57% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
Baxter International	-9.27%	16.57%	5.24%

In the previous week, Baxter International had 25 more articles in the media than LivaNova. MarketBeat recorded 30 mentions for Baxter International and 5 mentions for LivaNova. Baxter International's average media sentiment score of 1.00 beat LivaNova's score of 0.14 indicating that Baxter International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Baxter International	15 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.15	-$242.47M	$3.38	23.51
Baxter International	$11.47B	1.18	-$957M	-$2.07	N/A

Summary

LivaNova beats Baxter International on 12 of the 16 factors compared between the two stocks.

How does LivaNova compare to Penumbra?

Penumbra (NYSE:PEN) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 2.9% of Penumbra shares are owned by company insiders. Comparatively, 0.4% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Penumbra had 2 more articles in the media than LivaNova. MarketBeat recorded 7 mentions for Penumbra and 5 mentions for LivaNova. Penumbra's average media sentiment score of 1.54 beat LivaNova's score of 0.14 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
LivaNova	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LivaNova has a net margin of 12.82% compared to Penumbra's net margin of 10.67%. LivaNova's return on equity of 16.35% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
LivaNova	12.82%	16.35%	7.76%

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.50B	8.49	$177.69M	$4.07	79.67
LivaNova	$1.39B	3.15	-$242.47M	$3.38	23.51

Penumbra has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Penumbra currently has a consensus target price of $367.07, suggesting a potential upside of 13.20%. LivaNova has a consensus target price of $83.50, suggesting a potential upside of 5.09%. Given Penumbra's higher possible upside, equities research analysts clearly believe Penumbra is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

Summary

Penumbra beats LivaNova on 10 of the 16 factors compared between the two stocks.

How does LivaNova compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Smith & Nephew SNATS has higher revenue and earnings than LivaNova.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	1.99	$625M	N/A	N/A
LivaNova	$1.39B	3.15	-$242.47M	$3.38	23.51

In the previous week, Smith & Nephew SNATS had 6 more articles in the media than LivaNova. MarketBeat recorded 11 mentions for Smith & Nephew SNATS and 5 mentions for LivaNova. Smith & Nephew SNATS's average media sentiment score of 0.82 beat LivaNova's score of 0.14 indicating that Smith & Nephew SNATS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Smith & Nephew SNATS has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

LivaNova has a net margin of 12.82% compared to Smith & Nephew SNATS's net margin of 0.00%. LivaNova's return on equity of 16.35% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
LivaNova	12.82%	16.35%	7.76%

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by insiders. Comparatively, 0.4% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Smith & Nephew SNATS presently has a consensus price target of $30.93, indicating a potential upside of 5.95%. LivaNova has a consensus price target of $83.50, indicating a potential upside of 5.09%. Given Smith & Nephew SNATS's higher probable upside, analysts plainly believe Smith & Nephew SNATS is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

Summary

LivaNova beats Smith & Nephew SNATS on 8 of the 14 factors compared between the two stocks.

How does LivaNova compare to Globus Medical?

Globus Medical (NYSE:GMED) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, Globus Medical had 2 more articles in the media than LivaNova. MarketBeat recorded 7 mentions for Globus Medical and 5 mentions for LivaNova. Globus Medical's average media sentiment score of 0.71 beat LivaNova's score of 0.14 indicating that Globus Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Globus Medical has higher revenue and earnings than LivaNova. Globus Medical is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.80	$537.87M	$3.91	21.25
LivaNova	$1.39B	3.15	-$242.47M	$3.38	23.51

Globus Medical has a net margin of 17.02% compared to LivaNova's net margin of 12.82%. LivaNova's return on equity of 16.35% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
LivaNova	12.82%	16.35%	7.76%

Globus Medical has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

95.2% of Globus Medical shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 18.4% of Globus Medical shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Globus Medical presently has a consensus target price of $101.77, suggesting a potential upside of 22.49%. LivaNova has a consensus target price of $83.50, suggesting a potential upside of 5.09%. Given Globus Medical's stronger consensus rating and higher probable upside, equities analysts clearly believe Globus Medical is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

Summary

Globus Medical beats LivaNova on 14 of the 17 factors compared between the two stocks.

How does LivaNova compare to Glaukos?

LivaNova (NASDAQ:LIVN) and Glaukos (NYSE:GKOS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

In the previous week, Glaukos had 21 more articles in the media than LivaNova. MarketBeat recorded 26 mentions for Glaukos and 5 mentions for LivaNova. Glaukos' average media sentiment score of 0.89 beat LivaNova's score of 0.14 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	7 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

97.6% of LivaNova shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Comparatively, 5.9% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

LivaNova presently has a consensus price target of $83.50, indicating a potential upside of 5.09%. Glaukos has a consensus price target of $178.08, indicating a potential downside of 1.43%. Given LivaNova's higher probable upside, equities analysts clearly believe LivaNova is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Glaukos has lower revenue, but higher earnings than LivaNova. Glaukos is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.15	-$242.47M	$3.38	23.51
Glaukos	$612.84M	17.39	-$187.69M	-$3.25	N/A

LivaNova has a net margin of 12.82% compared to Glaukos' net margin of -30.68%. LivaNova's return on equity of 16.35% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
Glaukos	-30.68%	-6.37%	-4.78%

Summary

LivaNova and Glaukos tied by winning 8 of the 16 factors compared between the two stocks.

Get LivaNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIVN vs. The Competition

Export

Metric	LivaNova	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.37B	$5.79B	$7.32B	$12.76B
Dividend Yield	N/A	1.75%	2.54%	10.78%
P/E Ratio	23.48	26.21	271.20	24.17
Price / Sales	3.15	79.06	696.57	128.56
Price / Cash	16.28	33.71	29.03	36.89
Price / Book	3.61	6.20	11.33	6.51
Net Income	-$242.47M	$149.30M	$3.46B	$347.63M
7 Day Performance	-0.51%	0.96%	3.12%	1.53%
1 Month Performance	1.62%	9.22%	8.67%	5.17%
1 Year Performance	41.00%	7.57%	27.37%	17.69%

LivaNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIVN LivaNova	2.5828 of 5 stars	$79.46 +1.5%	$83.50 +5.1%	+40.0%	$4.37B	$1.39B	23.48	3,300
BAX Baxter International	1.7455 of 5 stars	$25.89 -3.1%	$22.45 -13.3%	+8.2%	$13.82B	$11.24B	N/A	37,500	Positive News Analyst Revision
PEN Penumbra	3.7253 of 5 stars	$326.86 0.0%	$367.07 +12.3%	+22.3%	$12.88B	$1.40B	80.31	4,700	Positive News
SNN Smith & Nephew SNATS	2.53 of 5 stars	$29.69 -0.4%	$30.93 +4.2%	-21.0%	$12.46B	$6.30B	N/A	16,988	News Coverage Analyst Upgrade
GMED Globus Medical	4.1416 of 5 stars	$85.11 -0.9%	$101.77 +19.6%	+34.5%	$11.53B	$2.94B	21.77	6,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIVN) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LivaNova (LIVN) Competitors

LIVN vs. BAX, PEN, SNN, GMED, and GKOS

How does LivaNova compare to Baxter International?

Summary

How does LivaNova compare to Penumbra?

Summary

How does LivaNova compare to Smith & Nephew SNATS?

Summary

How does LivaNova compare to Globus Medical?

Summary

How does LivaNova compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIVN vs. The Competition

LivaNova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LivaNova (LIVN) Competitors

LIVN vs. BAX, PEN, SNN, GMED, and GKOS

How does LivaNova compare to Baxter International?

Do insiders and institutionals hold more shares of LIVN or BAX?

Which has more risk & volatility, LIVN or BAX?

Do analysts recommend LIVN or BAX?

Is LIVN or BAX more profitable?

Does the media prefer LIVN or BAX?

Which has better earnings & valuation, LIVN or BAX?

Summary

How does LivaNova compare to Penumbra?

Do institutionals & insiders hold more shares of PEN or LIVN?

Does the media refer more to PEN or LIVN?

Is PEN or LIVN more profitable?

Which has preferable valuation and earnings, PEN or LIVN?

Which has more risk & volatility, PEN or LIVN?

Do analysts prefer PEN or LIVN?

Summary

How does LivaNova compare to Smith & Nephew SNATS?

Which has preferable valuation & earnings, SNN or LIVN?

Does the media favor SNN or LIVN?

Which has more risk and volatility, SNN or LIVN?

Is SNN or LIVN more profitable?

Do insiders and institutionals believe in SNN or LIVN?

Do analysts rate SNN or LIVN?

Summary

How does LivaNova compare to Globus Medical?

Does the media refer more to GMED or LIVN?

Which has stronger valuation & earnings, GMED or LIVN?

Is GMED or LIVN more profitable?

Which has more risk & volatility, GMED or LIVN?

Do institutionals and insiders hold more shares of GMED or LIVN?

Do analysts rate GMED or LIVN?

Summary

How does LivaNova compare to Glaukos?

Does the media prefer LIVN or GKOS?

Which has more volatility and risk, LIVN or GKOS?

Do insiders & institutionals believe in LIVN or GKOS?

Do analysts recommend LIVN or GKOS?

Which has better earnings & valuation, LIVN or GKOS?

Is LIVN or GKOS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIVN vs. The Competition

LivaNova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools